Insulin glargine and lixisenatide Subcutaneous and Panatuss DXP
Determining the interaction of Insulin glargine and lixisenatide Subcutaneous and Panatuss DXP and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
Generic Name: dexbrompheniramine / dextromethorphan / phenylephrine
Brand name: Alahist CF, G-P-Tuss DXP, Panatuss DXP, Supress A Pediatric, Alahist DM, Bionatuss, Supress A, Tussall, Tussall-ER, Dexall, Y-Cof DM, Panatuss Pediatric DXP
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin glargine and lixisenatide Subcutaneous-Panatuss PED
- Insulin glargine and lixisenatide Subcutaneous-Panatuss PED Drops
- Insulin glargine and lixisenatide Subcutaneous-Pancof HC
- Insulin glargine and lixisenatide Subcutaneous-Pancof XP
- Insulin glargine and lixisenatide Subcutaneous-Pancreatin
- Insulin glargine and lixisenatide Subcutaneous-Pancreatin 4X
- Panatuss DXP-Insulin glargine, recombinant Subcutaneous
- Panatuss DXP-Insulin glulisine
- Panatuss DXP-Insulin Glulisine (Cartridges and Pens)
- Panatuss DXP-Insulin Glulisine (Vials)
- Panatuss DXP-Insulin glulisine Subcutaneous
- Panatuss DXP-Insulin human inhaled Inhalation